Deans' stroke musings: Alzheimer's Association Joins Global Consortium to Strengthen the Drug Pipeline for Brain Diseases

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, November 18, 2014

Alzheimer's Association Joins Global Consortium to Strengthen the Drug Pipeline for Brain Diseases

Completely f*cking appalling, NO stroke association involved. I don't care if stroke is not a neurodegeneration disease, there could be lots of solutions repurposed for stroke. We have no one in stroke with even two neurons to rub together. Stupidity personified.
http://act.alz.org/site/R?i=bq8i3FRET9bj-vfI-2k2iQ

Today, the Alzheimer's Association announced its leadership role in the Neurodegeneration Medicines Acceleration Program (Neuro-MAP), which plans to uncover promising drugs for degenerative brain diseases in pharmaceutical company libraries and put them into early-stage clinical trials. Many potential drugs are languishing in laboratories because the companies who own them have moved in other directions. By identifying these projects and moving them forward, Neuro-MAP aims to bring these drugs closer to the people who desperately need them.

Partners in Neuro-MAP are: Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society (UK), ALS Association, Michael J. Fox Foundation for Parkinson's Research, Motor Neurone Disease Association, MRC Technology, Northern Health Science Alliance, and Parkinson's UK. The consortium represents more than 50 million people living with neurodegenerative conditions worldwide.

Neuro-MAP will ask pharmaceutical and biotechnology companies to propose projects to the consortium. The Neuro-MAP partner organizations will decide which projects to take on by evaluating patient needs, scientific excellence and commercial potential. Projects taken on by Neuro-MAP remain the property of the industry partner, but the consortium will share in a proportion of the revenue generated if the product goes on the market. These funds will be reinvested in additional research.

Consortium program manager, MRC Technology, will augment the initial investment from Neuro-MAP partners by seeking co-investment from the pharmaceutical and biotechnology industries, social investors, and venture philanthropists. As a result, the current target for total annual investment is in the region of $48 million.